An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Canagliflozin 50 mg

One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks

DRUG

Placebo

1 placebo capsule taken orally twice daily with a meal for 18 weeks

DRUG

Canagliflozin 150 mg

1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks

DRUG

Metformin

The patient's stable daily dose of Metformin background therapy should be continued throughout the study.

Trial Locations (61)

Unknown

Little Rock

National City

Spring Valley

Bradenton

Marianna

Savannah

Avon

Valparaiso

Madisonville

Metairie

Charlotte

Columbus

Mason

Perrysburg

Tulsa

Yukon

Oregon City

Pittsburgh

East Providence

Nashville

Houston

Pearland

San Antonio

Bountiful

Virginia Beach

Milwaukee

St. John's

Halifax

Brampton

Toronto

Saskatoon

Beroun

Olomouc

Ostrava

Pardubice

Písek

Prague

Znojmo

Aguascalientes

Guadalajara, Jalisco.

Monterrey

Tampico

Bacau

Brasov

Bucharest

Cluj-Napoca

Galati

Târgu Mureş

Kursk

Moscow

Saint Petersburg

Samara

Saratov

Tyumen

Voronezh

Banská Bystrica

Bratislava

Košice

Prešov

Šahy

Trebišov

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01340664 - An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy | Biotech Hunter | Biotech Hunter